Terms: = Germ cell tumor AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184 AND Staging
5 results:
1. Volumetric Parameters Derived from cxcr4-Directed PET/CT Predict Outcome in Patients with Gastrointestinal Neuroendocrine Carcinomas.
Michalski K; Schlötelburg W; Hartrampf P; Heinrich M; Serfling S; Buck AK; Werner RA; Kosmala A; Weich A
Mol Imaging Biol; 2024 Apr; 26(2):344-350. PubMed ID: 38332341
[TBL] [Abstract] [Full Text] [Related]
2. New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms.
Fortunati E; Argalia G; Zanoni L; Fanti S; Ambrosini V
Curr Treat Options Oncol; 2022 May; 23(5):703-720. PubMed ID: 35325412
[TBL] [Abstract] [Full Text] [Related]
3. Molecular Imaging in neuroendocrine neoplasias.
Christ E; Wild D; Refardt J
Presse Med; 2022 Jun; 51(2):104115. PubMed ID: 35131317
[TBL] [Abstract] [Full Text] [Related]
4. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine tumors - a Triple Tracer Comparative Approach.
Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C
Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632
[TBL] [Abstract] [Full Text] [Related]
5. Clincopathological analysis of olfactory neuroblastoma.
Fukushima S; Sugita Y; Niino D; Mihashi H; Ohshima K
Brain Tumor Pathol; 2012 Oct; 29(4):207-15. PubMed ID: 22331316
[TBL] [Abstract] [Full Text] [Related]
